Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Experimental Hematology & Oncology|November 28, 2025
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targetingÁngeles Ocaña-Cara, Tuna Mutis, Jort J van der Schans
Blood|July 2, 2002
Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantationTuna Mutis, Els Blokland, Michel Kester, et al.
European Journal of Immunology|April 17, 2008
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cellsTineke Aarts-Riemens, Maarten E Emmelot, Leo F Verdonck, et al.
Molecular Vision|January 1, 2014
Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathyJonas J W Kuiper, Maarten E Emmelot, Aniki Rothova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapyRobbert Spaapen, Kelly van den Oudenalder, Roman Ivanov, et al.
Frontiers in Oncology|August 28, 2020
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell TreatmentJort J van der Schans, Niels W C J van de Donk, Tuna Mutis
Blood|January 25, 2002
General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responsesJoke M M den Haan, Tuna Mutis, Els Blokland, et al.
Cancers|October 22, 2020
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell MalignanciesHilma J van der Horst, Inger S Nijhof, Tuna Mutis, et al.
Frontiers in Immunology|July 9, 2020
Targeted Therapy With Immunoconjugates for Multiple MyelomaWassilis S C Bruins, Sonja Zweegman, Tuna Mutis, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Exclusive TCRVbeta chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratypingRob M Verdijk, Tuna Mutis, Martina Wilke, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Experimental Hematology & Oncology|November 28, 2025
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targetingÁngeles Ocaña-Cara, Tuna Mutis, Jort J van der Schans
Blood|July 2, 2002
Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantationTuna Mutis, Els Blokland, Michel Kester, et al.
European Journal of Immunology|April 17, 2008
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cellsTineke Aarts-Riemens, Maarten E Emmelot, Leo F Verdonck, et al.
Molecular Vision|January 1, 2014
Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathyJonas J W Kuiper, Maarten E Emmelot, Aniki Rothova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapyRobbert Spaapen, Kelly van den Oudenalder, Roman Ivanov, et al.
Frontiers in Oncology|August 28, 2020
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell TreatmentJort J van der Schans, Niels W C J van de Donk, Tuna Mutis
Blood|January 25, 2002
General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responsesJoke M M den Haan, Tuna Mutis, Els Blokland, et al.
Cancers|October 22, 2020
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell MalignanciesHilma J van der Horst, Inger S Nijhof, Tuna Mutis, et al.
Frontiers in Immunology|July 9, 2020
Targeted Therapy With Immunoconjugates for Multiple MyelomaWassilis S C Bruins, Sonja Zweegman, Tuna Mutis, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Exclusive TCRVbeta chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratypingRob M Verdijk, Tuna Mutis, Martina Wilke, et al.
Pageof 11